Top Markets
Coin of the day
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Classement en actions #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Prix de l'action
$43.48
Capitalisation boursière
$8.97B
Changement (1 jour)
0.37%
Changement (1 an)
192.01%
Pays
US
Échange Immunovant, Inc. (IMVT)

Catégorie

Ratio P/B pour Immunovant, Inc. (IMVT)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Immunovant, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Immunovant, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH